

# Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy (N Engl J med 2021)

**RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL**

**768**

- Women with Fibroid-associated heavy menstrual bleeding (>80ml)
- Age: 18 to 50 years
- Z Score > -2
- no hormonal treatment

**Combination Therapy**  
(40mg Relugolix, 1mg Estradiol, 0,5mg norethindrone acetate for 24 Weeks)

**n=253**

**Delayed Relugolix Combination Therapy**  
(12W only Relugolix+12W Combination Therapy)

**n=259**

**PLACEBO**

**n=256**


## RESPONSE

1. Vol. of menstrual blood loss <80ml and a <50% reduction in volume from baseline
2. Amenorrhea, distress from bleeding and pelvic discomfort, Uterin volume(not single Fibroid volume)

**72%**

**76,5%**

**17%**



**Bone mineral density was similar with Relugolix combination Therapy and placebo, but decreased with Relugolix monotherapy**